Information Provided By: 
Fly News Breaks for November 29, 2016
ABBV, MNTA
Nov 29, 2016 | 13:08 EDT
Maxim analyst Jason McCarthy noted that Momenta (MNTA) announced that M923, its biosimilar version of Humira, met the primary endpoint in a trial of its efficacy, but added that the question about the product "is not efficacy, it is legal." If M923 is approved, a fight over IP with AbbVie (ABBV) could delay the commercial launch to 2022 or later, said McCarthy, who keeps a Sell rating on Momenta shares.
News For MNTA;ABBV From the Last 2 Days
There are no results for your query MNTA;ABBV
